News

Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.

Ogeda is engaged in the discovery and development of small molecule drugs that target G-protein coupled receptors (GPCRs). Under the deal, Astellas will pay around €500m for 100% equity

The trial will feature 80-120 patients having the severe form of the disease who will be randomized to receive treatment with either mepolizumab or placebo when added to the

The results were presented in an oral session (OR08-1) at ENDO 2017, the Endocrine Society's Annual Meeting in Orlando, Fla. In the study, postmenopausal women with low bone

DPI and MDI devices are the most common forms of drug delivery in non-hospitalized patients with COPD and are well-suited for the maintenance therapy of COPD patients.  The

The approval has been granted to treat patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test whose disease has progressed on or after an

The 11 successful projects were selected through a competitive process from 168 applications from around the world. The awarded grants were based on the merits of each of

Agenus plans to close its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities, and phase out approximately 50 positions across the organization.

The study’s primary objective was to test safety and tolerability of anabasum in adults with CF who had FEV1 ≥ 40% predicted and remained on background CF medications,